Tag: aromataseInhibitors

Articles

• ER+/PR+ breast cancer
• How important is Vitamin D before and after breast cancer diagnosis?
• How to optimize your breast cancer diet
• Latest research concerning impact of endocrine therapy on breast cancer prognosis
• What should breast cancer survivors eat during aromatase inhibitor treatment?
• What should hormone receptor positive (ER+/PR+) breast cancer patients and survivors eat?

News

• Aromatase inhibitor only or after tamoxifen are both effective treatments
• Aromatase inhibitors can increase risk of early hip fracture in breast cancer survivors
• Aromatase inhibitors can worsen cholesterol profile
• Aromatase inhibitors can worsen sexual function after breast cancer
• Aromatase inhibitors have numerous side effects in addition to musculoskeletal symptoms
• Bisphosphonate Zometa might increase survival in certain premenopausal breast cancer cases
• Bisphosphonates for treating osteoporosis may significantly reduce risk of breast cancer
• Breast cancer in old age
• Chemotherapy might have different effectiveness in lobular compared to ductal breast cancer
• Cognitive function improves after completion of both Femara and tamoxifen treatment
• Genistein stimulates aromatase activity and ER+ breast cancer cell growth
• High circulating hormones increase risk of breast cancer for postmenopausal women
• High dose vitamin D reduces musculoskeletal symptoms in women taking Arimidex
• How much red wine is safe for breast cancer survivors?
• Increasingly severe side effects of aromatase inhibitors may make tamoxifen first the best strategy
• Obesity increases inflammation and estrogen production in breast tissue
• Patients with ER-/PR+ breast cancer benefit from endocrine therapy
• Soy supplements do not reduce breast cancer risk and could be harmful
• Strongly estrogen positive lobular breast cancer responds well to neoadjuvant Femara
• Survival times of stage IV breast cancer patients depends on progesterone receptor status
• Switch in aromatase inhibitors can enable some with breast cancer to continue AI treatment
• Tamoxifen treatment results in cognitive impairment compared to Aromasin
• Treatment with aromatase inhibitors results in better breast cancer outcomes than tamoxifen
• Tumor response to anti-estrogen treatment before surgery is influenced by BMI and race
• Vitamin D deficiency promotes growth of breast cancer bone metastases
• Vitamin D levels often low even in breast cancer survivors taking supplements
• Vitamin D supplementation might interfere with aromatase inhibitor treatment
• Weight gain can increase hot flashes in breast cancer survivors on aromatase inhibitors
• Women with high BMI may benefit less from hormonal treatments

Foods

• blueberries  cranberries  genistein and daidzein  mushrooms  pomegranates 

Studies

• Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer
• An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs)
• Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients
• Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO
• Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients
• Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers
• Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer
• Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer
• Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
• Breast cancer in the very elderly: Staging, treatment, and outcomes in patients over age 80
• Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer
• Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial
• Changes in Weight and Body Composition in Women Receiving Chemotherapy for Breast Cancer
• Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole
• Deep Time: The Long and the Short of Adjuvant
• Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo
• Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
• Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy
• Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
• Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma
• Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
• Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer
• Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer
• Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
• Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle
• Evaluating Letrozole and Tamoxifen Alone and in Sequence at 8 Years Median Follow-up for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer
• Final 5-year results of Z-FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole
• Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model
• HDAC inhibitors trigger the autophagic switch from prosurvival to prodeath in tamoxifen-treated breast cancer cells
• Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer
• Induced sex reversal using an aromatase inhibitor, Fadrozole, in Atlantic halibut (Hippoglossus hippoglossus L.)
• Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer
• Invasive lobular carcinoma: response to neoadjuvant letrozole therapy
• Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic
• Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre
• Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial
• Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
• Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark
• Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland
• Obesity Linked to Worse Outcomes in Early Breast Cancer Treatment
• Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole
• Red Versus White Wine as a Nutritional Aromatase Inhibitor in Premenopausal Women
• Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer
• Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients
• Risk of second breast cancer according to estrogen receptor status and family history
• Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)
• Sexual Function after Breast Cancer
• Side effects associated with aromatase inhibitor treatment among breast cancer patients
• The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study
• The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors
• The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial
• Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
• Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial
• Vitamin D Deficiency in Post-Menopausal Breast Cancer Survivors
• Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors
• Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer